Eclitasertib also achieved numerically greater improvement in other inflammatory biomarkers including some of the markers of COVID-19 severity (leukocytes, neutrophil/lymphocyte ratio, LDH, IL-6, IL-8, and IL-6/IL-10) than placebo. This evidence concerns the gene IL6 and COVID-19.